|
Basic Characteristics of Mutations
|
|
Mutation Site
|
T115I |
|
Mutation Site Sentence
|
In addition, a decreased expression of IFN-gamma induced by ORF1ab3061 mut and ORF7a105 T115I mut peptides was repeatedly observed in three experiments, indicating that mutations in these five regions were likely involved in the immune escape of the viral variants. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
ORF7a |
|
Standardized Encoding Gene
|
ORF7a
|
|
Genotype/Subtype
|
B.1.1.284 |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
COVID-19
|
|
Immune
|
Y |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
- |
|
Location
|
Japan |
|
Literature Information
|
|
PMID
|
37124420
|
|
Title
|
COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient
|
|
Author
|
Morita R,Kubota-Koketsu R,Lu X,Sasaki T,Nakayama EE,Liu YC,Okuzaki D,Motooka D,Wing JB,Fujikawa Y,Ichida Y,Amo K,Goto T,Hara J,Shirano M,Yamasaki S,Shioda T
|
|
Journal
|
iScience
|
|
Journal Info
|
2023 May 19;26(5):106685
|
|
Abstract
|
A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during the infection period, with at least five mutations associated with host cellular immune recognition. Among them, the T32I mutation in ORF3a was found to evade recognition by CD4(+) T cells. The virus found after relapse showed an increased proliferative capacity in vitro. SARS-CoV-2 may have evolved to evade recognition by CD4(+) T cells and increased in its proliferative capacity during the persistent infection, likely leading to relapse. These mutations may further affect viral clearance in hosts with similar types of human leukocyte antigens. The early elimination of SARS-CoV-2 in immunocompromised patients is therefore important not only to improve the condition of patients but also to prevent the emergence of mutants that threaten public health.
|
|
Sequence Data
|
GSE190895;GISAD: EPI_ISL_4935777;GISAD: EPI_ISL_4935949;GISAD: EPI_ISL_4936095;GISAD: EPI_ISL_4936243;GISAD: EPI_ISL_4936533
|